A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
Latest Information Update: 14 Dec 2021
Price :
$35 *
At a glance
- Drugs Risankizumab (Primary) ; Methotrexate
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Sponsors AbbVie
- 29 Nov 2021 Status changed from active, no longer recruiting to completed.
- 25 Apr 2021 Primary endpoint (Percentage of participants with Static Physician Global Assessment (sPGA) score of clear or almost clear (0, 1) at Week 28.) has been met according to the results presented at the American Academy of Dermatology Virtual Meeting Experience 2021
- 25 Apr 2021 Primary endpoint (Percentage of participants with a 90% reduction from Baseline Psoriasis Area and Severity Index (PASI 90) at Week 28) has been met according to the results presented at the American Academy of Dermatology Virtual Meeting Experience 2021